Collegium Pharmaceutical (COLL) Non-Current Debt (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Non-Current Debt of $531.7 million for Q1 2026, down 0.74% year-over-year from $535.7 million in Q1 2025, and down 1.92% quarter-over-quarter from $542.1 million in Q4 2025.
Collegium Pharmaceutical (COLL) Non-Current Debt (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Non-Current Debt history runs 13 years deep, the most recent figure standing at $531.7 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 0.74% year-over-year to $531.7 million; the TTM figure through Mar 2026 stood at $531.7 million (down 0.74% YoY), while the FY2025 annual figure was $542.1 million, down 1.57% from the prior year.
- Non-Current Debt for Q1 2026 stood at $531.7 million, down from $542.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $565.7 million in Q3 2024, with the low at $132.8 million in Q2 2024.
- The 5-year median for Non-Current Debt is $484.9 million (2022), against an average of $415.6 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt jumped 544.73% in 2022, then sank 57.13% in 2024.
- Collegium Pharmaceutical's Non-Current Debt stood at $397.6 million in 2022, then sank by 44.23% to $221.7 million in 2023, then soared by 148.4% to $550.7 million in 2024, then retreated by 1.57% to $542.1 million in 2025, then retreated by 1.92% to $531.7 million in 2026.
- Business Quant data shows COLL's Non-Current Debt at $531.7 million in Q1 2026, $542.1 million in Q4 2025, and $505.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 130.00 Mn |
| 10 | Collegium Pharmaceutical | 889.75 Mn | 740.43 Mn | 110.29 Mn | 797.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 797.82 Mn |
| Mar 31, 2026 | 531.72 Mn |
| Dec 31, 2025 | 542.11 Mn |
| Sep 30, 2025 | 505.58 Mn |
| Jun 30, 2025 | 520.65 Mn |
| Mar 31, 2025 | 535.70 Mn |
| Dec 31, 2024 | 550.73 Mn |
| Sep 30, 2024 | 565.72 Mn |
| Jun 30, 2024 | 132.85 Mn |
| Mar 31, 2024 | 177.36 Mn |
| Dec 31, 2023 | 221.71 Mn |
| Sep 30, 2023 | 265.89 Mn |
| Jun 30, 2023 | 309.90 Mn |
| Mar 31, 2023 | 353.77 Mn |
| Dec 31, 2022 | 397.58 Mn |
| Sep 30, 2022 | 441.26 Mn |
| Jun 30, 2022 | 484.85 Mn |
| Mar 31, 2022 | 528.39 Mn |
| Dec 31, 2021 | 61.67 Mn |
| Sep 30, 2021 | 73.83 Mn |